Author + information
- Yashashwi Pokharela,b,
- Puza Sharmaa,b,
- Mohammed Qintara,b,
- Yuanyuan Tanga,b,
- Philip Jonesa,b,
- Rachel Dreyera,b and
- John Spertusa,b
Background: Despite statin therapy, patients with recent myocardial infarction (MI) and elevated high sensitivity C reactive protein (hsCRP) are at increased risk for adverse cardiovascular outcomes. Whether elevated hsCRP is associated with poor health status (symptoms, function and quality of life) among patients with history of MI is unknown.
Methods: TRIUMPH and VIRGO are prospective registries of MI that collected hsCRP 1 month after MI, along with generic (EQ5D and Short Form12 [SF12]) and disease-specific (Seattle Angina Questionnaire, SAQ) health status at 12 months. Sequential models were developed to examine the association of hsCRP (≥2.0 vs. <2 mg/L) with health status outcomes. In sensitivity analyses, we used hsCRP with cutoff of 3 mg/L and as a continuous variable, including non-linear associations using restricted cubic splines.
Results: Among 3410 patients, 59% and 52% had hsCRP ≥2 and ≥3 mg/L at 1 month, respectively. Statin therapy was used in 92% of patients at discharge. In unadjusted models, elevated hsCRP was associated with worsening health status, even after adjustment for 1-month health status (Table). No significant associations were observed after further adjustment for patient comorbidites. Results were similar in sensitivity analyses.
Conclusions: Although elevated hsCRP is associated with worse health status after MI, this is attenuated after adjusting for comorbidities, suggesting that hsCRP may be a marker of other comorbidities associated with worse health status.
Poster Hall, Hall C
Saturday, March 18, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Innovations in Cardiovascular Risk Assessment and Reduction
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1235-055
- 2017 American College of Cardiology Foundation